Adalimumab biosimilars prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for adalimumab biosimilars (Hadlima, Adalimumab-bwwd, Simlandi, Yusimry, brand adalimumab) across multiple indications for CareOregon members; defines initial and reauthorization requirements and prescriber specialties.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
Initial authorization lengths commonly 6 months as specified by indication.
Reauthorization — Covered when ALL of the following are met
Covered when ALL of the following are met
Reauthorization approval lengths commonly 12 months as specified by indication.
Crohn's Disease — Covered when ALL of the following are met
Covered when ALL of the following are met
Authorization parameters note first auth day 0-21: MDD 0.22; second auth day 22-180: no MDD.
Hidradenitis Suppurativa — Covered when ALL of the following are met
Covered when ALL of the following are met
Initial approval commonly 6 months; reauthorization commonly 12 months. Reauthorization response criteria include ≥25% reduction in total abscess and inflammatory nodule count or no increase in abscesses/draining fistulas.
Juvenile Idiopathic Arthritis — Covered when ALL of the following are met
Covered when ALL of the following are met
Reauthorization requires ≥20% improvement in tender and swollen joint counts or improvement in functional ability.
Non-infectious Uveitis — Covered when ALL of the following are met
Covered when ALL of the following are met
Reauthorization requires submission of medical records confirming disease control (no inflammation, no new lesions, no vitreous haze or decreased visual acuity).
Plaque Psoriasis — Covered when ALL of the following are met
Covered when ALL of the following are met
Initial approval commonly 6 months; reauthorization commonly 12 months.
Plaque Psoriasis (Hadlima / adalimumab products) — Plaque psoriasis covered when ALL of the following are met
Plaque psoriasis — covered when ALL of the following are met
Authorization parameters note first auth day 0-21: MDD 0.22; second auth day 22-180: no MDD.
Psoriatic Arthritis — covered when ONE of the following condition sets is met
Psoriatic arthritis — covered when ONE of the following condition sets is met
Rheumatoid Arthritis — Covered when ALL of the following are met
Covered when ALL of the following are met
Ulcerative Colitis — Covered when ALL of the following are met
Covered when ALL of the following are met
Requests for adalimumab biosimilars or brand adalimumab must not be prescribed concurrently with another biologic agent. The policy explicitly states that the requested product will not be used in combination with another biologic as a condition of approval for multiple indications and authorization pathways.
Concurrent use of an adalimumab product with any other biologic is excluded and will not be approved. Multiple indication-specific sections reiterate that approval requires the agent not be used in combination with another biologic, and requests proposing combined biologic therapy will be denied.
Requests that do not document required prior therapy trials or objective evidence of moderate‑to‑severe disease where specified, or that lack documented infection risk screening (including initial latent TB testing and treatment if indicated), are at risk for denial. The guideline requires indication‑specific prior therapy trials/failures and baseline severity measures (for example, BASDAI for axial SpA) and explicit documentation that infection risk was addressed before initiation.
Requests missing documentation of required prior therapy trials/failures, an infection risk assessment (including initial latent TB testing and treatment if needed and confirmation of no active infection), or appropriate specialist prescriber/consultation notes (dermatology, rheumatology, or gastroenterology as indicated) will be considered not medically necessary. The policy also requires documentation of risks/benefits where chronic or recurrent infection history exists.
Coding and Authorization Parameters
| GPI10 | Authorization approval parameter referenced for drug grouping |
| GPI10 | Authorization approval parameter / product grouping indicator referenced in document |
Provider Actions and Documentation Requirements
Prior authorization required for adalimumab products
Prior authorization is required for the listed adalimumab products (Hadlima, Adalimumab-bwwd, Simlandi, Yusimry, and brand adalimumab); approval lengths are specified by indication (commonly 6 months initial; 12 months for reauthorization).
Authorization durations vary by diagnosis
Prior authorization must be obtained for these adalimumab products; initial and reauthorization approval durations vary by diagnosis — for many indications initial approval is 6 months and reauthorization is 12 months (see indication-specific criteria).
Required prior trials and failures for most indications
Most indications require documented trials and failures of specified prior therapies before approval (examples shown per diagnosis).
- Ankylosing spondylitis: trial and failure of at least two NSAIDs for 3 months at max tolerated dose and physical therapy (and for ages ≥21: IV infliximab) (chunk 4).
- Hidradenitis suppurativa: trial and failure of specified antibiotic regimens, intralesional corticosteroids, antiandrogenic hormonal treatments or acitretin (and for ages ≥21: IV infliximab) (chunk 8).
- Plaque psoriasis: trial and failure of high‑potency topical corticosteroids plus a non‑steroid topical, an oral DMARD, and phototherapy (and for ages ≥21: IV infliximab) (chunk 18).
Document required conventional therapy trials before approval
For multiple diagnoses, approval requires documented trials and failures of specified conventional therapies relevant to the condition before biologic therapy is approved.
- Plaque psoriasis: high‑potency topical corticosteroid + non‑steroid topical, oral DMARD (methotrexate, cyclosporine, or acitretin), and phototherapy (chunk 18).
- Psoriatic arthritis: NSAIDs and methotrexate or other DMARDs (leflunomide, sulfasalazine, cyclosporine) (chunk 21).
- Rheumatoid arthritis: methotrexate 20 mg/week for ≥8 weeks plus another DMARD (leflunomide, hydroxychloroquine, or sulfasalazine) (chunk 22).
Submit medical records to support reauthorization
For reauthorization, submit medical records (e.g., chart notes) confirming disease control or improvement as specified by the diagnosis.
- Examples include lack of inflammation, no new inflammatory vascular lesions, no vitreous haze, or no decreases in visual acuity for uveitis (chunk 16).
Required documentation with request
Documentation submitted with the prior authorization request must include the diagnosis, details of prior treatment trials and failures per the indication, infection risk assessment, and prescriber specialty consultation notes.
- Include prior therapies such as DMARDs, NSAIDs, phototherapy, and infliximab where age‑appropriate (chunks 18, 21, 22).
- Provide evidence of initial latent TB testing and treatment if necessary and confirmation of no active infection (chunks 19, 24).
- Include documentation of specialist prescribing or consultation (dermatologist, rheumatologist, or gastroenterologist) as indicated (chunks 19, 21, 24).
Denial risk if diagnosis criteria or prior therapy not documented
Requests that do not meet the diagnosis‑specific criteria risk denial; common causes include lack of documented moderate‑to‑severe disease where required, missing prior therapy trials/failures, or absent infection/TB screening.
- Examples: missing objective evidence (e.g., BASDAI for AS), absent required trials (e.g., NSAIDs, DMARDs), or no latent TB testing documented (chunks 4, 24).
Do not combine with another biologic
Concurrent use of another biologic with an adalimumab product will not be approved; combination biologic therapy is prohibited.
Background
Adalimumab and its biosimilars are tumor necrosis factor (TNF) inhibitors indicated across multiple inflammatory conditions including ankylosing spondylitis/axial spondyloarthritis, Crohn's disease, hidradenitis suppurativa, juvenile idiopathic arthritis, non‑infectious uveitis, and plaque psoriasis. Because TNF inhibition increases infection risk, the guideline requires initial latent TB testing and treatment if necessary, confirmation of no active infection prior to starting therapy, and documentation of infection‑related risks and benefits for patients with chronic or recurrent infections.
Definitions
Initial Therapy Requirements
inv-36: Initial therapy requirements — Initial authorization requires indication-specific baseline severity and prior therapy trials/failures.
Initial authorization requires indication-specific baseline severity and prior therapy trials/failures.
Initial approval lengths commonly 6 months depending on indication; MDD parameters apply to certain auth periods as noted per diagnosis.
inv-37: Initial Therapy — Initial approval requires documented indication, prior therapy trials/failures, and infection risk mitigation.
Initial approval requires documented indication, prior therapy trials/failures, and infection risk mitigation.
Authorization parameters and MDD values apply per diagnosis and auth period as specified in the guideline.
Reauthorization / Continuation Requirements
inv-38: Reauthorization requirements — Reauthorization granted when member demonstrates improvement or maintained disease control per indication-specific measures.
Reauthorization granted when member demonstrates improvement or maintained disease control per indication-specific measures.
Reauthorization approval lengths commonly 12 months; documentation (chart notes) required.
inv-39: Continuation / Reauthorization — Reauthorization/continuation criteria require evidence of prior response or maintained remission.
Reauthorization/continuation criteria require evidence of prior response or maintained remission.
Step Therapy Requirements
| Requirement | Details / Examples |
|---|---|
| Documented trial(s) of specified conventional therapies | |
| Examples by indication: AS/axial SpA — trial and failure of ≥2 NSAIDs for 3 months at max tolerated dose plus physical therapy; HS — trial and failure of specified antibiotic regimens, intralesional corticosteroids, antiandrogenic hormonal treatments (women), acitretin when appropriate; JIA — systemic corticosteroids and a ≥3 month trial of methotrexate or leflunomide (or contraindication); Uveitis — topical glucocorticoids ≥1 month or periocular steroid injections plus an immunomodulator; Psoriasis — high‑potency topical steroid + non‑steroid topical, oral DMARD (methotrexate, cyclosporine, or acitretin) and phototherapy; PsA/RA/UC — trial and failure of NSAIDs, methotrexate or other DMARDs as specified. |
| Required documentation | What must be shown |
|---|---|
| Prior trial and inadequate response or intolerance to listed therapies | |
| Must document clinical evidence of inadequate response or intolerance to the specified prior therapies (for example: lack of improvement after topical/systemic therapies and phototherapy for psoriasis; failure of methotrexate 20 mg/week ≥8 weeks plus another DMARD for RA; failure of NSAIDs and methotrexate/other DMARDs for PsA). | |
| Clinical baseline severity and specialty consultation | |
| Document diagnosis and baseline disease severity where required (e.g., BASDAI for axial SpA, Hurley Stage II/III for HS, physician global ≥5 for JIA, PASI baseline for psoriasis) and note prescriber specialty or consultation (dermatology, rheumatology, gastroenterology, or ophthalmology as applicable). | |
| Infection risk assessment and TB testing | |
| Initial testing for latent TB and treatment if needed, affirmation of no active infection, and documentation of risks/benefits for chronic or recurrent infection prior to initiation. |
Quantity Limits
Site of Care Considerations
IV infliximab referenced as prior therapy (age ≥21)
IV infliximab is referenced as an alternative prior therapy for certain pathways and applies to patients age 21 and older; the policy does not mandate a specific infusion site but references IV therapy as a prior step.
- IV infliximab is listed as a required or considered prior therapy for ages ≥21 in multiple indications (chunks 8, 18).
IV infliximab prior‑therapy references limited to age ≥21
References to IV infliximab as a prior therapy apply only to patients age 21 and older; adalimumab products are outpatient‑administered and the infliximab requirement is limited to specified pathways.
- Multiple indication pathways note 'Only for those age 21 and older: IV infliximab' (chunks 6, 24).
Biosimilar and Brand Guidance
Biosimilars and brand adalimumab are interchangeable for authorization
The policy treats the listed adalimumab biosimilars and brand adalimumab interchangeably for prior authorization purposes; the biosimilars named include Hadlima, Adalimumab‑bwwd, Simlandi, and Yusimry.
Listed adalimumab products included in guideline
These specific adalimumab branded and biosimilar products (Hadlima, Adalimumab‑bwwd, Simlandi, Yusimry, and brand adalimumab) are included in the prior authorization guideline and are referenced interchangeably for covered indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.